Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | AKT2 | P31751 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1455345 | 1.00 | PIM1 (0.39) | PIM1AKT2SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL1455360 | 0.93 | PIM1 (0.38) | PIM1AKT2ALDH1A1HPGDS | |
| SCHEMBL1455364 | 0.93 | PIM1 (0.38) | PIM1AKT2ALDH1A1HPGDS | |
| SCHEMBL1456236 | 0.93 | PIM1 (0.36) | PIM1AKT2SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL1456239 | 0.93 | PIM1 (0.36) | PIM1AKT2SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL1454859 | 0.93 | ROCK2 (0.38) | PIM1AKT2 | |
| SCHEMBL1454862 | 0.93 | ROCK2 (0.38) | PIM1AKT2 | |
| SCHEMBL1456084 | 0.92 | PIM1 (0.40) | PIM1AKT2 | |
| SCHEMBL1455643 | 0.92 | PIM1 (0.40) | PIM1AKT2 | |
| SCHEMBL1454751 | 0.92 | PIM1 (0.40) | PIM1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979348-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-01-18 | — | — | EP | disclosed |
| US-7910595-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-22 | — | — | US | disclosed |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | PIM1 2963/4885AKT2 3903/4885SMN1; SMN2 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.